Last reviewed · How we verify
Denosumb
Denosumb, marketed by Turku University Hospital, is a drug with a key composition patent expiring in 2028. The primary strength of Denosumb lies in its current market presence, leveraging its established mechanism and primary indication. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Denosumb |
|---|---|
| Also known as | Brand name: Prolia |
| Sponsor | Turku University Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer (PHASE3)
- Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Denosumb CI brief — competitive landscape report
- Denosumb updates RSS · CI watch RSS
- Turku University Hospital portfolio CI